Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. J Oncol Pharm Pract 2019 Sep;25(6):1516-1519

Date

08/10/2018

Pubmed ID

30089432

DOI

10.1177/1078155218791309

Scopus ID

2-s2.0-85052579205 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

We report a case of a non-secretory neuroendocrine tumor which transformed into an insulin secreting tumor after treatment with Sunitinib. To our knowledge, this has only been described in three other cases worldwide. Previously reported case series find transformation of non-secretory neuroendocrine cancers into secretory lesions occurs in 3.4-6.8% of cases. Sunitinib is known to have the potential to lower blood glucose and induce epigenetic changes in cells of various types. We hypothesize that the mechanism for Sunitinib-induced transformation in cancer phenotype is through epigenetic changes in DNA expression within the tumor cells.

Author List

Clover T, Abdelkader A, Guru Murthy GS

Author

Guru Subramanian Guru Murthy MD Assistant Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Cell Transformation, Neoplastic
Humans
Insulinoma
Male
Middle Aged
Neuroendocrine Tumors
Pancreatic Neoplasms